Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC
Albumin-bound paclitaxel plus carboplatin is an effective and well-tolerated first-line treatment in patients with advanced non-small-cell lung cancer, irrespective of histology, study results show.
Source: MedWire News - Respiratory - Category: Respiratory Medicine Source Type: news
More News: Abraxane | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Respiratory Medicine | Study